Sandra Sanders-van Wijk

Post doc

Dr Sandra Sanders-van Wijk graduated cum laude at the WereDi scholengemeenschap Valkenswaard in 2003 (Gymnasium/VWO). She received her master’s diploma Medicine (Geneeskunde) at Maastricht University in 2010 and obtained her doctorate/PhD thesis in 2015, entitled ‘Biomarkers in heart failure: towards individualized therapy’, focussing on clinical heart failure (HF) and biomarker research (promotor Prof. H.P. Brunner-La Rocca). She started her clinical training in cardiology (cardioloog in opleiding) in 2014 (expected end date January 2021). She won the Netherlands Heart Institute fellowship in 2018; a grant to do a 6 month post-doc abroad, spend at Northwestern University/Memorial hospital with Prof. S.J. Shah studying biomarkers in HFpEF (November 2018-April 2019). Published >20 peer-reviewed articles and 2 editorials. She has presented her research results at >10 national and international scientific conferences and was awarded ‘best speaker’ in the HF session of the Dutch cardiology conference (NVVC) in 2012. She is a reviewer for e.g. European Journal of Heart Failure.

Her current research focus is clinical research in heart failure in general and HFpEF in particular. Biomarkers (mainly circulating biomarkers) remain an area of interest and are employed to unravel disease processes, to better diagnose and to target therapy, using different holistic system biology approaches such as network & pathway analyses, mediation analysis, cluster analysis etc. Alongside biomarkers, her research focusses on general clinical and pathophysiological issues in HF, such as integrated care, eHealth applications, iron deficiency, influence of comorbidities in HF and for HFpEF specifically the focus is on inflammation and endothelial dysfunction. She has particular interest and knowledge of advanced statistical modelling/bioinformatics and database building/management (R/SPSS/Microsoft access/Cytoscape/Metascape etc).


Department of Cardiology
P. Debyelaan 25, 6229 HX Maastricht 
PO Box 5800, 6202 AZ Maastricht
T: +31(0)630 412 408

  • 2021
    • Amin, H., Weerts, J., Brunner-La Rocca, H. P., Knackstedt, C., & Sanders-van Wijk, S. (2021). Future perspective of heart failure care: benefits and bottlenecks of artificial intelligence and eHealth. Future Cardiology, 17(6), 917-921.
    • Marcks, N., Aimo, A., Januzzi, J. L., Vergaro, G., Clerico, A., Latini, R., Meessen, J., Anand, I. S., Cohn, J. N., Gravning, J., Ueland, T., Bayes-Genis, A., Lupón, J., de Boer, R. A., Yoshihisa, A., Takeishi, Y., Egstrup, M., Gustafsson, I., Gaggin, H. K., ... Brunner-La Rocca, H-P. (2021). Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. Clinical research in cardiology, 110(8), 1280-1291.
    • Parcha, V., Malla, G., Kalra, R., Patel, N., Wijk, S. S., Pandey, A., Shah, S. J., Arora, G., & Arora, P. (2021). Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems. Esc heart failure, 8(3), 2089-2102.
    • Sanders-van Wijk, S., Barandiaran Aizpurua, A., Brunner-La Rocca, H-P., Henkens, M. T. H. M., Weerts, J., Knackstedt, C., Uszko-Lencer, N., Heymans, S., & van Empel, V. (2021). The HFA-PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction. European journal of heart failure, 23(5), 838-840.
    • Aizpurua, A. B., Sanders-van Wijk, S., Brunner-La Rocca, H. P., Henkens, M. T. H. M., Weerts, J., Spanjers, M. H. A., Knackstedt, C., & van Empel, V. P. M. (2021). Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction. Esc heart failure, 8(2), 1304-1313.
  • 2020
    • Lanfear, D. E., Luzum, J. A., She, R., Gui, H., Donahue, M. P., O'Connor, C. M., Adams, K. F., Sanders-van Wijk, S., Zeld, N., Maeder, M. T., Sabbah, H. N., Kraus, W. E., Brunner-La Rocca, H-P., Li, J., & Williams, L. K. (2020). Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure. Circulation-Heart Failure, 13(12), [007012].
    • Sanders-van Wijk, S., Tromp, J., Beussink-Nelson, L., Hage, C., Svedlund, S., Saraste, A., Swat, S. A., Sanchez, C., Njoroge, J., Tan, R-S., Fermer, M. L., Gan, L-M., Lund, L. H., Lam, C. S. P., & Shah, S. J. (2020). Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction Results From the PROMIS-HFpEF Study. Circulation, 142(21), 2029-2044.
    • Henkens, M. T. H. M., Remmelzwaal, S., Robinson, E. L., van Ballegooijen, A. J., Aizpurua, A. B., Verdonschot, J. A. J., Raafs, A. G., Weerts, J., Hazebroek, M. R., Wijk, S. S., Handoko, M. L., den Ruijter, H. M., Lam, C. S. P., de Boer, R. A., Paulus, W. J., van Empel, V. P. M., Vos, R., Brunner-La Rocca, H-P., Beulens, J. W. J., & Heymans, S. R. B. (2020). Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. European journal of heart failure, 22(9), 1586-1597.
    • Stohr, R., Brandenburg, V. M., Heine, G. H., Maeder, M. T., Leibundgut, G., Schuh, A., Jeker, U., Pfisterer, M., Sanders-van Wijk, S., & Brunner-La Rocca, H. P. (2020). Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial. European journal of heart failure, 22(4), 701-709.
    • Barutaut, M., Fournier, P., Peacock, W. F., Evaristi, M. F., Caubere, C., Turkieh, A., Desmoulin, F., Eurlings, L. W. M., van Wijk, S., Brunner-La Rocca, H-P., Butler, J., Koukoui, F., Dambrin, C., Mazeres, S., Le Page, S., Delmas, C., Galinier, M., Jung, C., Smih, F., & Rouet, P. (2020). Insulin-like Growth Factor Binding Protein 2 predicts mortality risk in heart failure. International Journal of Cardiology, 300, 245-251.